[{"id":"0a6aefb7-2166-498d-888e-ed54ef581ee3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00792948","created_at":"2021-01-18T03:00:33.783Z","updated_at":"2025-02-25T12:25:29.112Z","phase":"Phase 2","brief_title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00792948","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 01/06/2026","study_completion_date":" 01/06/2026","last_update_posted":"2025-02-24"},{"id":"d69d9e8b-481b-4b6a-a241-66952601f3da","acronym":"RITZ","url":"https://clinicaltrials.gov/study/NCT05735834","created_at":"2023-02-21T16:01:53.200Z","updated_at":"2025-02-25T14:03:19.754Z","phase":"Phase 3","brief_title":"Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients","source_id_and_acronym":"NCT05735834 - RITZ","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" MYD88 • CCND1 • BCL6 • IL2RA • MME • ITGAE • ISG20","pipe":" | ","alterations":" IL2RA expression","tags":["MYD88 • CCND1 • BCL6 • IL2RA • MME • ITGAE • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/21/2024","start_date":" 05/21/2024","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-19"},{"id":"f5056d6b-3ffd-4e44-961f-b461e0552213","acronym":"A051902","url":"https://clinicaltrials.gov/study/NCT04803201","created_at":"2021-03-17T15:57:46.362Z","updated_at":"2025-02-25T14:15:53.168Z","phase":"Phase 2","brief_title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT04803201 - A051902","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 10/08/2021","start_date":" 10/08/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-18"},{"id":"b1018fa9-fe4d-453b-84e2-5cea26a0b9e5","acronym":"NCI-2016-01300","url":"https://clinicaltrials.gov/study/NCT02879695","created_at":"2021-01-18T14:08:12.480Z","updated_at":"2025-02-25T16:51:44.591Z","phase":"Phase 1","brief_title":"Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia","source_id_and_acronym":"NCT02879695 - NCI-2016-01300","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19 • CD34 • MME","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD34 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Blincyto (blinatumomab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/25/2017","start_date":" 10/25/2017","primary_txt":" Primary completion: 05/22/2023","primary_completion_date":" 05/22/2023","study_txt":" Completion: 07/18/2025","study_completion_date":" 07/18/2025","last_update_posted":"2025-02-04"},{"id":"879fd467-51b3-46e4-9863-a9475f8f4f72","acronym":"Oracle","url":"https://clinicaltrials.gov/study/NCT03593018","created_at":"2021-01-18T17:39:39.095Z","updated_at":"2025-02-25T14:27:18.930Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL","source_id_and_acronym":"NCT03593018 - Oracle","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • azacitidine • bendamustine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 11/09/2018","start_date":" 11/09/2018","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-10-09"},{"id":"259ce71b-5eef-4e8b-8117-2864d12c696a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01472562","created_at":"2021-01-18T06:08:26.175Z","updated_at":"2025-02-25T14:33:09.941Z","phase":"Phase 2","brief_title":"Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT01472562","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD20 • CCND1 • CD5 • CCND2 • MME • FCER2","pipe":" | ","alterations":" CCND1 overexpression • CCND2 overexpression","tags":["CD20 • CCND1 • CD5 • CCND2 • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression • CCND2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 07/29/2011","start_date":" 07/29/2011","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 07/30/2023","study_completion_date":" 07/30/2023","last_update_posted":"2024-07-16"},{"id":"1d85dbcc-99da-47ba-8c97-bc3ae2e635f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06499168","created_at":"2025-02-26T14:29:49.967Z","updated_at":"2025-02-26T14:29:49.967Z","phase":"","brief_title":"Predicting Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer","source_id_and_acronym":"NCT06499168","lead_sponsor":"Assiut University","biomarkers":" MME","pipe":"","alterations":" ","tags":["MME"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-07-12"},{"id":"cc241a5c-7c68-406b-b95d-f9f314fccafd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03939182","created_at":"2021-02-03T10:56:06.215Z","updated_at":"2024-07-02T16:34:36.776Z","phase":"Phase 1","brief_title":"Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma","source_id_and_acronym":"NCT03939182","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BCL6 • IRF4 • MME","pipe":"","alterations":" ","tags":["BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • abexinostat (CG-781)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/29/2019","start_date":" 05/29/2019","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-10"},{"id":"5c1628c8-1205-4db1-a7b7-2787115fd94d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03620903","created_at":"2021-01-18T17:47:32.533Z","updated_at":"2024-07-02T16:35:04.143Z","phase":"Phase 2","brief_title":"Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT03620903","lead_sponsor":"Christian Buske","biomarkers":" CD20 • CD5 • MME • FCER2","pipe":" | ","alterations":" CD5 positive","tags":["CD20 • CD5 • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • bortezomib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 09/11/2019","start_date":" 09/11/2019","primary_txt":" Primary completion: 11/14/2022","primary_completion_date":" 11/14/2022","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2024-05-13"},{"id":"68c8de81-678c-4539-bf83-7836e390592f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01788020","created_at":"2021-01-18T07:53:54.903Z","updated_at":"2024-07-02T16:35:04.236Z","phase":"Phase 3","brief_title":"Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT01788020","lead_sponsor":"University of Ulm","biomarkers":" CD20 • CD5 • MME • FCER2","pipe":" | ","alterations":" CD20 positive • CD5 positive","tags":["CD20 • CD5 • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • cyclophosphamide • dexamethasone • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 202","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-05-13"},{"id":"90515a21-3e57-41de-96be-20611fb49d4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065554","created_at":"2021-10-04T12:52:56.869Z","updated_at":"2025-02-25T15:00:05.879Z","phase":"Phase 2","brief_title":"ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy","source_id_and_acronym":"NCT05065554","lead_sponsor":"Shayna Sarosiek, MD","biomarkers":" CD20 • CD22 • IL2RA • CD5 • SDC1 • CD27 • MME • ITGAE • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD22 • IL2RA • CD5 • SDC1 • CD27 • MME • ITGAE • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 11/16/2021","start_date":" 11/16/2021","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2024-04-17"},{"id":"e1b1beee-8596-4e66-9c4b-6af0006c827e","acronym":"RV-CL-PTCL-PI-003974","url":"https://clinicaltrials.gov/study/NCT02232516","created_at":"2021-01-18T10:28:31.078Z","updated_at":"2025-02-25T14:34:54.612Z","phase":"Phase 2","brief_title":"Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT02232516 - RV-CL-PTCL-PI-003974","lead_sponsor":"Northwestern University","biomarkers":" ALK • CD20 • CD8 • TNFRSF8 • PAX5 • CD4 • NCAM1 • CD5 • CXCL13 • GZMB • MME • CD7 • UBR5","pipe":" | ","alterations":" ALK negative","tags":["ALK • CD20 • CD8 • TNFRSF8 • PAX5 • CD4 • NCAM1 • CD5 • CXCL13 • GZMB • MME • CD7 • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Istodax (romidepsin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/11/2015","start_date":" 06/11/2015","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-04-10"},{"id":"788595e2-1e53-44d0-a30d-f936e3886bd2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03407859","created_at":"2021-01-18T16:48:50.152Z","updated_at":"2024-07-02T16:35:14.654Z","phase":"Phase 1","brief_title":"Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL","source_id_and_acronym":"NCT03407859","lead_sponsor":"Zhujiang Hospital","biomarkers":" CD20 • CD22 • MME","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD22 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/18/2016","start_date":" 01/18/2016","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-03-15"},{"id":"bdb1c58a-74c6-4750-9dd9-d9830096d0d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03291444","created_at":"2021-01-18T16:15:39.130Z","updated_at":"2024-07-02T16:35:14.542Z","phase":"Phase 1","brief_title":"CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS","source_id_and_acronym":"NCT03291444","lead_sponsor":"Zhujiang Hospital","biomarkers":" KIT • CD20 • IL6 • CD38 • WT1 • CD22 • CD33 • CD34 • NCAM1 • MME • IL3RA","pipe":" | ","alterations":" CD20 positive","tags":["KIT • CD20 • IL6 • CD38 • WT1 • CD22 • CD33 • CD34 • NCAM1 • MME • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/05/2018","start_date":" 05/05/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-15"},{"id":"d41013a9-659b-4bd4-843d-44f12482f427","acronym":"STELLA","url":"https://clinicaltrials.gov/study/NCT02475707","created_at":"2021-01-18T11:55:12.467Z","updated_at":"2024-07-02T16:35:31.622Z","phase":"Phase 1","brief_title":"Administration of Donor MultiTAA-Specific T Cells for ALL","source_id_and_acronym":"NCT02475707 - STELLA","lead_sponsor":"Baylor College of Medicine","biomarkers":" CD8 • CD4 • MME","pipe":"","alterations":" ","tags":["CD8 • CD4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MultiTAA T cell therapy"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 10/29/2019","primary_completion_date":" 10/29/2019","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-10-26"},{"id":"8a4f4c76-2dc0-425a-a17a-009310b1b1fb","acronym":"IELSG37","url":"https://clinicaltrials.gov/study/NCT01599559","created_at":"2021-01-18T06:50:23.394Z","updated_at":"2024-07-02T16:35:32.505Z","phase":"Phase 3","brief_title":"Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma","source_id_and_acronym":"NCT01599559 - IELSG37","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" BCL2 • CD20 • TNFRSF8 • BCL6 • PTPRC • IRF4 • MME","pipe":" | ","alterations":" CD20 positive","tags":["BCL2 • CD20 • TNFRSF8 • BCL6 • PTPRC • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 540","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 06/17/2022","primary_completion_date":" 06/17/2022","study_txt":" Completion: 12/17/2029","study_completion_date":" 12/17/2029","last_update_posted":"2023-10-19"},{"id":"883c093f-d2f2-4bdb-a6df-2c4fb2930bc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05890352","created_at":"2023-06-06T14:06:56.792Z","updated_at":"2024-07-02T16:35:34.556Z","phase":"Phase 2","brief_title":"Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment","source_id_and_acronym":"NCT05890352","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" MYC • BCL2 • BCL6 • IRF4 • MME","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Brukinsa (zanubrutinib) • Tazverik (tazemetostat) • Monjuvi (tafasitamab-cxix)"],"overall_status":"Recruiting","enrollment":" Enrollment 227","initiation":"Initiation: 09/26/2023","start_date":" 09/26/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 01/01/2029","study_completion_date":" 01/01/2029","last_update_posted":"2023-10-05"},{"id":"499207e6-901b-4535-b7c7-217df099a09a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06064344","created_at":"2023-10-03T19:11:19.311Z","updated_at":"2024-07-02T16:35:34.954Z","phase":"","brief_title":"RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma","source_id_and_acronym":"NCT06064344","lead_sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","biomarkers":" BCL2 • CD20 • CCND1 • CD22 • CD5 • CD79A • MME • FCER2","pipe":"","alterations":" ","tags":["BCL2 • CD20 • CCND1 • CD22 • CD5 • CD79A • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 10/07/2023","start_date":" 10/07/2023","primary_txt":" Primary completion: 10/06/2027","primary_completion_date":" 10/06/2027","study_txt":" Completion: 10/06/2027","study_completion_date":" 10/06/2027","last_update_posted":"2023-10-03"},{"id":"c97d7329-c4ce-4484-ae03-d5fac150b05b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04224571","created_at":"2021-01-18T20:33:58.003Z","updated_at":"2024-07-02T16:35:38.657Z","phase":"Phase 2","brief_title":"CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children","source_id_and_acronym":"NCT04224571","lead_sponsor":"Chinese University of Hong Kong","biomarkers":" MME","pipe":"","alterations":" ","tags":["MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib"],"overall_status":"Completed","enrollment":" Enrollment 208","initiation":"Initiation: 09/14/2018","start_date":" 09/14/2018","primary_txt":" Primary completion: 02/15/2023","primary_completion_date":" 02/15/2023","study_txt":" Completion: 02/15/2023","study_completion_date":" 02/15/2023","last_update_posted":"2023-08-30"},{"id":"b75c8e0c-7a34-42e8-acb6-f56117fba765","acronym":"","url":"https://clinicaltrials.gov/study/NCT03542266","created_at":"2022-11-13T19:37:00.102Z","updated_at":"2025-02-25T14:27:01.502Z","phase":"Phase 2","brief_title":"CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT03542266","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" ALK • PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 06/01/2018","start_date":" 06/01/2018","primary_txt":" Primary completion: 03/25/2020","primary_completion_date":" 03/25/2020","study_txt":" Completion: 07/25/2022","study_completion_date":" 07/25/2022","last_update_posted":"2023-08-22"},{"id":"a86eae23-5fcb-4a8b-a5e6-a0ef3b33f450","acronym":"","url":"https://clinicaltrials.gov/study/NCT02213913","created_at":"2021-01-18T10:22:23.451Z","updated_at":"2024-07-02T16:35:49.349Z","phase":"Phase 1/2","brief_title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","source_id_and_acronym":"NCT02213913","lead_sponsor":"University of Chicago","biomarkers":" MYC • BCL2 • CD20 • BCL6 • IRF4 • MME","pipe":" | ","alterations":" BCL2 positive","tags":["MYC • BCL2 • CD20 • BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 07/29/2014","start_date":" 07/29/2014","primary_txt":" Primary completion: 07/29/2023","primary_completion_date":" 07/29/2023","study_txt":" Completion: 07/29/2023","study_completion_date":" 07/29/2023","last_update_posted":"2023-04-28"},{"id":"aa427175-54cc-421c-9eb3-20e2eec8ad01","acronym":"","url":"https://clinicaltrials.gov/study/NCT03703375","created_at":"2021-01-18T18:08:54.175Z","updated_at":"2024-07-02T16:36:00.520Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma","source_id_and_acronym":"NCT03703375","lead_sponsor":"Celgene","biomarkers":" PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":"","alterations":" ","tags":["PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 11/06/2018","start_date":" 11/06/2018","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 02/29/2024","study_completion_date":" 02/29/2024","last_update_posted":"2022-11-14"},{"id":"6b1ce6aa-ed12-4b51-a62c-cf7d47ec0c53","acronym":"","url":"https://clinicaltrials.gov/study/NCT05262673","created_at":"2022-03-02T16:52:33.183Z","updated_at":"2024-07-02T16:36:15.843Z","phase":"Phase 1","brief_title":"NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL","source_id_and_acronym":"NCT05262673","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD20 • CD19 • CD22 • MME • IL3RA","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD19 • CD22 • MME • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-03-08"},{"id":"2946b700-5826-4d78-a718-85c3a3225263","acronym":"BGB-3111-207","url":"https://clinicaltrials.gov/study/NCT03145064","created_at":"2021-01-18T15:30:04.949Z","updated_at":"2024-07-02T16:36:21.005Z","phase":"Phase 2","brief_title":"Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT03145064 - BGB-3111-207","lead_sponsor":"BeiGene","biomarkers":" BCL6 • MME","pipe":"","alterations":" ","tags":["BCL6 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 06/30/2017","start_date":" 06/30/2017","primary_txt":" Primary completion: 05/24/2019","primary_completion_date":" 05/24/2019","study_txt":" Completion: 09/03/2020","study_completion_date":" 09/03/2020","last_update_posted":"2021-11-08"}]